MAPLE GROVE, Minn. – Upsher-Smith announced that it has expanded its fluoxetine product family with the launch of Fluoxetine Oral Solution, USP, 20 mg/5 mL. Upsher-Smith’s product is a generic version of the product, Prozac (fluoxetine) Oral Solution.

The fluoxetine oral solution market had U.S. sales of approximately $14.2 million for the 12 months ending November 2022 according to IQVIA.

“We are very excited to lead this calendar year off with the launch of Fluoxetine Oral Solution,” said Rich Fisher, president and COO, Upsher-Smith. “Upsher-Smith has many exciting things in store for 2023 including the opening of our world-class manufacturing facility in Maple Grove, MN, and a rich pipeline of high-quality generic products, positioning the Company for both near-term and future growth.”